The economics of gene therapy has captured just about everyone’s attention in the industry. This first wave is faced with stubborn questions about durability, the race to first-in-class status as well as the sticky issue of just how much money you can make from these supposedly once-and-done therapies that can cure patients of some terrible diseases.
BioMarin CEO Jean-Jacques Bienaimé felt the full force of that blowback from a range of analysts in yesterday’s Q4 call. And at one point in the conversation, he offered a snapshot of what the future could look like — and it’s a big one.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,100+ biopharma pros who read Endpoints News by email every day.Free Subscription